Akrivis Technologies, LLC is a privately-held biopharmaceutical company founded in 2009 and headquartered in Cambridge, MA. Akrivis is engaged in the early diagnosis and treatment of serious and life-threatening diseases. Akrivis’ main asset is its proprietary Z-TECT™ technology platform that provides ultrasensitive detection and accurate quantification of biomolecules present down to the zeptomole range (10E–21 moles). In addition to supporting in vitro and in vivo diagnostic applications, Z-TECT™ will also serve as a novel platform for the targeted delivery of high payloads of radio– and chemotherapeutic drugs for cancer therapy. Potentially providing far safer and more efficacious targeted delivery therapeutics, Z-TECT™ will have a major impact on the emerging field of “Theranostics” that combines cancer therapies with companion in vivo imaging.